The main objective of the project is to develop an innovative strategy for the treatment of cystic fibrosis using state-of-the-art technologies based on extracellular vesicles (EVs) and genome editing tools, such as the CRISPR/Cas9 system. As a result of mutations in the CFTR gene, patients often develop pneumonia, which in chronic conditions leads to pulmonary fibrosis. Despite the available pharmacological treatment, cystic fibrosis is an incurable disease, and patients live to 24-39 years. Therefore, there is a need to develop new therapies that will effectively eliminate the cause of the disease or significantly improve the lives of patients.To achieve the goal, the project, in close cooperation with the foreign scientific partner and the national economic partner, will use two innovative strategies for the treatment of cystic fibrosis, which are the two main pillars of this project. First, EVs will be used as carriers of the CRISPR/Cas9 system to achieve CFTR gene correction, based on a previously developed and patented technology (PCT/IB2018/055591, US 17/262,789, EP 18762920.9). The new genome editing strategy will be designed in close cooperation with the scientific partner Professor Toni Cathomen of the Medical Centre of the University of Albert-Ludwigs in Freiburg. The safety and effectiveness of gene correction will be verified using next-generation sequencing technology and bioinformatic analyses performed by our business partner Xenstats sp z o.o. In the second pillar, we will use an alternative solution to alleviate the symptoms of the disease in the form of EVs with increased antifibrotic activity (P.44827), which will be tested in in vivo models of pulmonary fibrosis.